Trastuzumab Deruxtecan for HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial
J. Clin. Oncol 2023 Mar 28;[EPub Ahead of Print], T Nishikawa, K Hasegawa, K Matsumoto, M Mori, Y Hirashima, K Takehara, K Ariyoshi, T Kato, S Yagishita, A Hamada, M Kawasaki, S Kawashima, S Tomatsuri, Y Nagasaka, H Yoshida, R Machida, A Hirakawa, K Nakamura, K YonemoriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.